logo-loader
HealthPharma & Biotech
viewAstraZeneca

AstraZeneca reports positive results from trial of pancreatic cancer treatment

Results from the trial of Lynparza showed “statistically significant and clinically meaningful improvement” in the time patients could live without their disease getting worse

Pancreatic
In 2018, there were 458,918 new cases of pancreatic cancer worldwide

AstraZeneca PLC (LON:AZN) said its Lynparza treatment nearly doubled the life-span of patients with metastatic pancreatic cancer in a phase III trial.

The trial tested Lynparza tablets as an initial maintenance treatment for metastatic pancreatic cancer patients, whose disease had not progressed after chemotherapy.

READ: AstraZeneca gets US regulatory green light for slow-release diabetes drug

Results showed “statistically significant and clinically meaningful improvement” in the time patients could live without their disease getting worse by an average of 7.4 months on Lynparza, compared to 3.8 months for those on placebo.

More than twice as many patients showed no disease progression both at one year and two years after starting to take Lynparza.  

José Baselga, executive vice president of oncology research and development, said: "These unprecedented results raise new hope for patients that have seen little progress over a long period of time.”

He said AstraZeneca is now working with regulatory authorities to bring Lynparza to patients “as quickly as possible”.

Pancreatic cancer has the worst survival rate of the most common cancers with less than 3% of patients surviving more than five years after diagnosis.

Early diagnosis of pancreatic cancer is difficult because there are usually no symptoms until it is too late.  About 80% of patients are diagnosed at the metastatic stage.

In 2018, there were 458,918 new cases of pancreatic cancer worldwide.

Quick facts: AstraZeneca

Price: 6729 GBX

LSE:AZN
Market: LSE
Market Cap: £882.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Primary Health Properties delivering 'impressive dividend track record and...

Proactive Research analyst Ed Stacey says Primary Health Properties (LON:PHP) has an impressive track record of dividend growth, increasing the payment every year since listing in 1997. On top of that he says they've delivered steady capital gains on its portfolio that have translated into...

3 hours, 31 minutes ago

2 min read